KRAS and cancer: Strengths of this study were the prospective design, exclusion of NSCLC patients that were treated with potentially mutagenic chemotherapy or radiotherapy, a precise protocol for tumor regions sampling for genetic analysis and random selection of patients for comparison of KRAS mutation status in cancer tissue, blood and EBC–DNA.